Blanca Molins

Dr. Blanca Molins

Institut d'Investigacions Biomèdiques Agusti Pi i Sunyer. Hospital Clinic Barcelona, 08036 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
SRSara Romero-Vazquez
Sara Romero-Vazquez
VLVictor Llorenç
Victor Llorenç
ASAlba Soler-Boronat
Alba Soler-Boronat
MFMarc Figueras-Roca
Marc Figueras-Roca
AAAlfredo Adan
Alfredo Adan
Blanca MolinsBlanca Molins
Blanca Molins
Age-related macular degeneration (AMD) heads the list of legal blindness among the elderly population in developed countries. Due to the complex nature of the retina and the variety of risk factors and mechanisms involved, the molecular pathways underlying AMD are not yet fully defined. Persistent low-grade inflammation and oxidative stress eventually lead to retinal pigment epithelium dysfunction and outer blood–retinal barrier (oBRB) breakdown. The identification of AMD susceptibility genes encoding complement factors, and the presence of inflammatory mediators in drusen, the hallmark deposits of AMD, supports the notion that immune-mediated processes are major drivers of AMD pathobiology. Complement factor H (FH), the main regulator of the alternative pathway of the complement system, may have a key contribution in the pathogenesis of AMD as it is able to regulate both inflammatory and oxidative stress responses in the oBRB. Indeed, genetic variants in the CFH gene account for the strongest genetic risk factors for AMD. In this review, we focus on the roles of inflammation and oxidative stress and their connection with FH and related proteins as regulators of both phenomena in the context of AMD.

1 October 2019 in Experimental Eye Research
Verified
Journal Article
Closed access
Blanca MolinsBlanca Molins
Blanca Molins
AMAdriana Mora
Adriana Mora
SRSara Romero-Vázquez
Sara Romero-Vázquez
APAnna Pascual-Méndez
Anna Pascual-Méndez
SRSara Rovira
Sara Rovira
JMJordi Martorell
Jordi Martorell

16 July 2020 in Aging
Verified
Journal Article
Open access
SRSara Romero-Vázquez
Sara Romero-Vázquez
AAAlfredo Adán
Alfredo Adán
MFMarc Figueras-Roca
Marc Figueras-Roca
VLVictor Llorenç
Victor Llorenç
MSMark Slevin
Mark Slevin
Blanca MolinsBlanca Molins
Blanca Molins
The retinal pigment epithelium (RPE) is considered one of the main targets of age-related macular degeneration (AMD), the leading cause of irreversible vision loss among the ageing population worldwide. Persistent low grade inflammation and oxidative stress eventually lead to RPE dysfunction and disruption of the outer blood-retinal barrier (oBRB). Increased levels of circulating pentameric C-reactive protein (pCRP) are associated with higher risk of AMD. The monomeric form (mCRP) has been detected in drusen, the hallmark deposits associated with AMD, and we have found that mCRP induces oBRB disruption. However, it is unknown how mCRP is generated in the subretinal space. Using a Transwell model we found that both pCRP and mCRP can cross choroidal endothelial cells and reach the RPE in vitro and that mCRP, but not pCRP, is able to cross the RPE monolayer in ARPE-19 cells. Alternatively, mCRP can originate from the dissociation of pCRP in the surface of lipopolysaccharide-damaged RPE in both ARPE-19 and primary porcine RPE lines. In addition, we found that the proinflammatory phenotype of mCRP in the RPE depends on its topological localization. Together, our findings further support mCRP contribution to AMD progression enhancing oBRB disruption.

25 September 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JMJessica Matas
Jessica Matas
VLVictor Llorenç
Victor Llorenç
AFAlex Fonollosa
Alex Fonollosa
DDDavid Díaz-Valle
David Díaz-Valle
CECristina Esquinas
Cristina Esquinas
Blanca MolinsBlanca Molins
Blanca Molins
Purpose: To investigate whether systemic immune mediators and circulating regulatory T cells (Tregs) could be prognostic factors for anatomic outcomes in macular edema secondary to non-infectious uveitis (UME). Methods: Multicenter, prospective, observational, 12-month follow-up study of 60 patients with UME. Macular edema was defined as central subfield thickness (CST) > 300 μm measured with spectral domain optical coherence tomography (SD-OCT). Serum samples and peripheral blood mononuclear cells (PBMC) were obtained from venous blood extraction at baseline. Serum levels of IL-1β, IL-6, IL-8, IL-17, MCP-1, TNF-α, IL-10, and VEGF were determined by Luminex. Tregs population, defined as CD3+CD4+FoxP3+ in PBMC, was determined by flow cytometry. Main outcome measure was the predictive association between searched mediators and CST sustained improvement, defined as CST < 300 microns or a 20% CST decrease, at 6 months maintained until 12-months compared to baseline levels. Results: Multivariate logistic regression analysis showed an association between CST sustained improvement at 12 months follow-up and IL-6 and Tregs baseline levels. Higher IL-6 levels were associated with less events of UME improvement (OR: 0.67, 95% CI (0.45–1.00), P = 0.042), whereas higher levels of Tregs favored such improvement (OR: 1.25, 95% CI: 1.12–2.56, P = 0.049). Conclusions: Increased levels of Tregs and reduced levels of IL-6 in serum may be prognostic factors of sustained anatomical improvement in UME. These findings could enforce the opportunity to develop more efficient and personalized therapeutic approaches to improve long-term visual prognosis in patients with UME.

8 March 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
MSMark Slevin
Mark Slevin
Blanca MolinsBlanca Molins
Blanca Molins
Editorial: C-Reactive Protein in Age-Related Disorders, Volume II